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Abstract
Background Interleukin-18 (IL-18) mediates ischemic
acute tubular necrosis; it has been proved as a rapid, reli-
able, and affordable test marker for the early detection of
acute kidney injury (AKI), but its predictive accuracy
varies greatly.
Methods MEDLINE and EMBASE, Cochrane Library,
Ovid, and Springerlink (from inception to November 15,
2013) were searched for relevant studies (in English)
investigating diagnostic accuracy of urine IL-18 to predict
AKI in various clinical settings. The text index was
increasing or increased urine IL-18 level and the main out-
come was the development of AKI, which was primarily
based on serum creatinine level [using risk, injury, failure,
loss and end-stage renal disease (RIFLE), acute kidney
injury network, or modified pediatric RIFLE criteria in
pediatric patients]. Pooled estimates of diagnostic odds ratio
(OR), sensitivity and specificity were calculated. Summary
receiver operating characteristic curves were used to calcu-
late the measures of accuracy and Q point value (Q*).
Remarkable heterogeneity was explored further by subgroup
analysis based on the different clinical settings.
Results We analyzed data from 11 studies of 3 countries
covering 2,796 patients. These studies were marked by
limitations of threshold and non-threshold effect hetero-
geneity. Across all settings, the diagnostic OR for urine IL-
18 level to predict AKI was 5.11 [95 % confidence interval
(CI) 3.22–8.12], with sensitivity and specificity respec-
tively at 0.51 and 0.79. The area under the ROC curve of
urine IL-18 level to predict AKI was 0.77 (95 % CI
0.71–0.83). Subgroup analysis showed that urine IL-18
level in pediatric patients (\18 years) and early AKI pre-
dictive time (\12 h) were more effective in predicting
AKI, with diagnostic ORs of 7.51 (2.99–18.88), 8.18
(2.19–30.51), respectively.
Conclusion Urine IL-18 holds promise as a biomarker in
the prediction of AKI but has only moderate diagnostic
value.
Keywords Interleukin-18  Acute kidney injury 
Predictive value  Systemic review
Introduction
As an abrupt or rapid decline in renal filtration function,
acute kidney injury (AKI) is a common condition associ-
ated with significant morbidity and mortality. In critically
ill patients, those with AKI usually present a worse clinical
outcome than their non-AKI counterparts [1]. Although
regarded as the standard indicators of kidney function loss,
serum creatinine (sCr) level and urine output are recog-
nized as having limitations. On the one hand, sCr cannot
accurately reflect the glomerular filtration rate (GFR) in a
patient with unsteady state, and urine output is easily
affected by water intake and the primary water load of the
body [2]. On the other hand, sCr and urine output have
limited sensitivity and specificity, and a delayed response
to kidney impairment. All these factors suggest that sCr
and urine output are not appropriate markers in the early
detection of AKI. Thus, an accurate and timely biomarker
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to predict AKI onset or progression after renal insult is
urgently needed.
Interleukin-18 (IL-18), a member of the IL-1 family
of cytokines, is synthesized as an inactive 23-kDa pre-
cursor by several tissues including monocytes, macro-
phages, and proximal tubular epithelial cells, and is
processed into an active 18.3 kDa cytokine by caspase-1
[3]. It has been demonstrated in some animal studies [4]
as a mediator of renal ischemia–reperfusion injury,
inducing acute tubular necrosis, and neutrophil and
monocyte infiltration of the renal parenchyma. More
recently, numerous clinical studies have focused on the
diagnostic accuracy of IL-18 level in predicting AKI [5–
7]. With the evidence accumulating, contradictory results
have raised concerns about the predictive value of AKI
across various settings. Thus, we performed a systematic
review and meta-analysis to investigate the diagnostic
accuracy of IL-18 level for predicting AKI. Since there
is no clear consensus about the appropriate cutoff level
of IL-18 to predict AKI and different thresholds have
been reported by different studies, the summary receiver
operating characteristic (sROC) curve was delineated for
the meta-analysis.
Methods
Data sources and search strategy
A computer-based search was performed in MEDLINE,
EMBASE, Cochrane Library, Ovid, and Springerlink dat-
abases, from inception until November 15, 2013, to iden-
tify potentially relevant articles. The search strategy
consisted of terms related to AKI (‘‘acute kidney injury’’
and ‘‘acute renal failure’’) combined with the term ‘‘inter-
leukin-18/interleukin 18/IL-18’’. To ensure all articles were
located, a secondary search of the articles already retrieved
was undertaken, reviewing their reference lists. The pre-
ferred reporting items for systematic reviews and meta-
analysis (PRISMA) guidelines for the conduct of meta-
analyses were followed [8].
Study selection
The titles and abstracts were examined independently by
two of the authors (X. L. and J. Y.) to ascertain their
relevance and inclusion for further analysis. Any dis-
agreements were settled by consensus using a third
opinion (Y. Z.). Inclusion criteria were that studies
investigated the diagnostic accuracy of urinary IL-18 to
predict AKI and had data which could be extracted into a
2 9 2 table or complete data which could be obtained
from the corresponding author by e-mail. The search was
restricted to human subjects. Only papers in English were
eligible.
Data extraction
The following variables were recorded or recalculated:
study population, sample size, age, sex, baseline IL-18
level, cutoff value for urine IL-18, AKI definition, number
of patients who developed AKI, timing of obtaining the
specimen, specificity, sensitivity, and area under the ROC
curve (AUROC) with 95 % confidence interval (CI). Data
for IL-18 sample storage and detection method were also
collected. Two reviewers independently excluded articles
on the basis of the title and abstract following a custom-
made standardized table. The true-positive, true-negative,
false-positive, and false-negative results of each included
study were quantified. Quality assessment was performed
using the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) tool [9] and independently by the
authors (X. L. and J. Y.).
Fig. 1 Flowchart representing study selection for systematic review
of urine IL-18 as a diagnostic marker for AKI. IL interleukin, AKI
acute kidney injury
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Statistical analysis
The meta-analysis was conducted using sROC curve as
described by Rosman [10] and the computation was per-
formed using Meta-Disc1.4. If multiple cutoff points were
adopted in any study, the cutoff point (test threshold),
sensitivity and specificity in this analysis were selected
according to the Youden index. Heterogeneity was quan-
titatively assessed using the Q statistic. Fixed or random
effects models (FEM or REM) were used on the basis of
heterogeneity. We performed subgroup analysis to explore
the remarkable heterogeneity in the light of different
clinical settings.
Results
Search results and study characteristics
Of 179 primary articles searched, 156 were excluded on the
basis of abstract and/or title because they were laboratory
studies, genetic studies, review/comment articles, animal
studies, or irrelevant to the current analysis; 3 were
excluded because non-English articles. Of the 20 remaining
articles, 5 studies with accurate diagnostic values of IL-18
missing and 3 studies lacking effective data (though we had
contacted the corresponding authors to request the missing
information) were excluded. As a result, 11 studies [6, 7,
Table 2 Quality assessment of individual studies























































































No Yes Yes Yes Yes No Yes
a This item is labeled ‘‘No’’ if the spectrum of patients was representative of patients who received the test in practice, otherwise it is labeled
‘‘Yes’’
b This item is labeled ‘‘No’’ when all patients received the same reference standard, otherwise it is labeled ‘‘Yes’’
c This item is labeled ‘‘Yes’’ if patients who were lost to follow-up differed systematically from those who remained, otherwise it is labeled
‘‘No’’
‘‘—’’ This item is not applicable if the study was retrospective in design
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11–19] met the inclusion criteria and were selected for the
analysis (Fig. 1).
Characteristics of the included trials are shown in Table 1.
Two come from China [6, 11], seven from the USA [7, 13, 14,
16–19], one from Taiwan, China [12], and one from Aus-
tralia [15]. Overall, 2,796 patients were comprised, ranging
from newborn to elderly age. Sample sizes were[100 in 7
studies and[1,000 in 1 [14]. Most studies were conducted on
critical patients, including those with cardiac surgery (car-
diopulmonary bypass) and transplantation, as well as various
intensive care patients. Five studies [6, 11, 13, 17, 18]
focused on pediatric patients. Males in all studies represented
[50 % of the study population. Eight studies defined AKI
using acute kidney injury network (AKIN) and/or risk,
injury, failure, loss and end-stage renal disease (RIFLE)
criteria, two [11, 17] using modified pediatric RIFLE, and
one [16] using sCr level which, however, rose to C50 % of
baseline in the first 72 h. Ten studies harnessed urine IL-18
concentration as the cutoff value and two [11, 15] the ratio of
urine IL-18 to urine-creatinine concentration.
Quality assessment
Table 2 lists the methodological quality assessment of the
included 11 studies. Ten studies enrolled single or mul-
ticenter consecutive patients prospectively, one [7] was
retrospective and prospective in design. The study by
Chen et al. [12] did not define inclusion and exclusion
criteria clearly. The reference standards used in the afore-
mentioned studies were creatinine based, which currently
is the most widely used standard for evaluating kidney
function. The conditions of follow-up were reported in the
10 prospective cohort studies; there were no selective
losses in them. Overall, the quality of the studies was
suboptimal, without sufficient information to assess all the
bias, and uninterpretable, indeterminate or intermediate
Table 3 Sensitivity and specificity of individual studies for urine IL-18 to predict AKI
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2 PM each day 39 7 64 27 75 38 78 0.54
(0.31–0.77)
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Every 2 h for the first 12 h and
then once every 12 h
5 1 15 34 50 25 97 0.61 4
10 2 10 33 50 50 94 0.75 12
12 4 8 31 20 60 89 0.73 24
Parikh et al.
[19]
Days 0, 1, and 3 38 29 14 57 25 74 66 0.731 24
IL interleukin, AKI acute kidney injury, AUROC area under the receiver operating characteristic curve, CI confidence interval, CPB cardio-
pulmonary bypass, FN false-negative, FP false-positive, TN true-negative, TP true-positive
a pg/mg uCr
b (pg/ml)/mmol/l Cr
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index test results were not reported. The quality assess-
ment was performed independently by the authors (X. L.
and J. Y.).
Data extraction and calculation
As the respective number of true-positive, false-positive,
true-negative, and false-negative results was not provided
by the studies, these indexes were calculated from avail-
able sensitivity, specificity, and sample size values. Results
are reported in Table 3 which enumerates specimen
obtaining times and AKI predictive times of each study.
Cutoff and AUROC values are also included in the table.
As can be seen, cutoff values for urine IL-18 varied across
studies.
Diagnostic value of urine IL-18 in AKI prediction
The distribution of accurate estimator in sROC curve floor
plan and the Spearman correlation coefficient (r = 0.764,
p = 0.006) of logarithmic sensitivity and logarithm (1-
specificity) showed that there was a threshold effect in
different studies (Fig. 2; Table 4).
Figure 3 shows the forest plots and pooled estimates of
sensitivity, specificity and diagnostic odds ratios (ORs)
respectively. We found a diagnostic OR of 5.11 (95 % CI
3.22–8.12) for urine IL-18 level to predict AKI (Cochran-
Q = 28.19, p = 0.0017) with a sensitivity and specificity
respectively of 0.51 (heterogeneity Chi-squared 84.53,
p \ 0.001) and 0.79 (heterogeneity Chi-squared 62.84,
p \ 0.001) (Fig. 3). Significant non-threshold effect het-
erogeneity was also disclosed across these studies. As there
was no statistically significant between b and 0
(p = 0.1870), the Mantel–Haenszel model was utilized to
draw the fitting curve of sROC (Fig. 4). The pooled AU-
ROC was 0.77 (95 % CI 0.71–0.83, Q = 0.71).
Subgroup analysis (Table 5) showed that urine IL-18
level in pediatric patients (\18 years) was more effective
in predicting AKI, with a diagnostic OR of 7.510 (95 %
CI 2.988–18.875) compared to 4.652 (2.710–7.987) for
the adult group (p = 0.334); the early AKI predictive
time (\12 h) subgroup displayed the highest diagnostic
OR of 8.176 (95 % CI 2.191–30.507) among the three
subgroups (\12, 24 and 48 h, p = 0.037). The pooled
estimate diagnostic OR of the admission subgroup was
3.81 (95 % CI 2.08–6.99) and that of the subgroup for
other times 7.16 (3.62–14.18). There were no significant
differences between the two (p = 0.388). There were
significant differences (p = 0.008) between cardiac sur-
gery patients and patients in intensive care unit or coro-
nary care unit patients in the subgroup analysis, with
diagnostic ORs of 5.28 (3.59–7.76) and 5.31
(2.59–10.87), respectively.
Discussion
The current study presents a meta-analysis of urine IL-18
for predicting AKI development via the sROC analysis
approach, both overall and across a range of subgroups.
Studies committed to direct comparisons between urine IL-
18 and the ‘‘gold standard’’ sCr were included. The finding
derived is consistent with previous studies, which lends
more force to the use of urine IL-18 as a marker of AKI in
clinical practice. The results of this meta-analysis indicate
that urine IL-18 had a pooled diagnostic OR of 5.11 and the
Fig. 2 The distribution of accurate estimator in sROC curve floor
plan. sROC summary receiver operating characteristic
Table 4 Analysis of diagnostic threshold
Spearman correlation coefficient: 0.764, p value = 0.006
Logit (TPR) vs. logit (FPR)
Moses’ model (D = a ? bS)
Weighted regression (inverse variance)
Var Coeff. Std. error T p value
a 1.791 0.254 7.061 0.0001
b(1) 0.224 0.157 1.428 0.1870
Tau-squared estimate = 0.1904 (convergence is achieved after 6
iterations)
Restricted maximum likelihood estimation (REML)
No. studies = 11 add 1/2 to all cells of the studies with zero
12 J Nephrol (2015) 28:7–16
123
Fig. 3 Forest plots and pooled estimates of a diagnostic odds ratio (OR), b sensitivity, and c specificity
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estimated area under the curve (AUC) of the mean ROC
plot was 0.77 (Q = 0.71), with a high heterogeneity in
pooled sensitivity and specificity. This suggests that urine
IL-18 has a higher chance of early detecting an AKI
compared to sCr, but the application of this biomarker in
the diagnosis of AKI should be limited to a certain range in
the light of limitations intrinsic to such studies. Since
pooled results may increase statistical power and lead to
more precise estimates of a treatment effect and the pooled
random or fixed effect models reflect the between-study
variance [20], this may shed light on larger populations.
Due to the presence of a threshold effect, we used sROC
curve fitting, the area under ROC and Q index, to merge the
data. In the studies included, cutoff values were expressed
in two types, urinary concentration or ratio of urine IL-18
and creatinine concentration, and identified as varying
across studies (11.25–125 pg/ml). Such differences can be
explained by: (1) use of different reagents in these studies
though the assay methods were enzyme-linked immuno-
sorbent assay (ELISA); and (2) differences in clinical set-
tings and study population. Therefore, it might be
necessary for each center using urine IL-18 level for early
AKI diagnosis to define a specific reference range and
cutoff value for each clinical setting.
In addition, a significant non-threshold effect heteroge-
neity exists across these studies. Since these studies were
based on different institutions across the world, heteroge-
neity was inevitable concerning differences in AKI defi-
nitions, AKI settings, times for obtaining specimen, and
experimental groups admitted to assess the predictive value
of urine IL-18. We attempted to use meta-regression to
explore the sources of heterogeneity, but failed. So sub-
group analysis was performed and proved that urine IL-18
level in pediatric patients and the early AKI predictive time
group (\12 h) was more effective in predicting AKI, which
might principally account for the heterogeneity. Never-
theless, as the kidney undergoes growth and maturation in
neonates who manifest different physiological states due to
the abrupt changes at birth, many risk factors are correlated
with AKI and the timing of kidney injury remains unknown
[21]. The metabolic capacity and compensatory ability of
neonates and children are also different from those of
adults [22]. Subgroup analysis of age should be more
specific if more clinical trials are conducted. Regarding
AKI definition, AKIN, RIFLE, AKIN and/or RIFLE, and
modified pediatric RIFLE criteria were adopted in the
different included studies. The pooled diagnostic OR of
AKI within 12 h was greater than that of 24 or 48 h in
subgroup analysis. This is useful in clinical processing
Fig. 4 The fitting curve of sROC
Table 5 Pooled diagnostic
accuracy of IL-18 in various
settings














Age \18 years 5 10.23 0.037 60.9 7.51 (2.99–18.88) 0.334
C18 years 6 15.54 0.008 67.8 4.32 (2.48–7.51)
Predictive time B12 h 5 18.27 0.001 78.1 8.18 (2.19–30.51) 0.037
24 h 4 4.48 0.214 33.0 5.07 (2.58–9.96)
48 h 5 5.04 0.283 20.7 4.95 (3.39–7.24)
Obtaining specimen Admission 4 13.4 0.004 77.6 3.81 (2.08–6.99) 0.388
Other times 7 10.38 0.109 42.4 7.16 (3.62–14.18)
Patients Cardiac surgery 4 0.59 0.90 0.01 5.28 (3.593–7.762) 0.008
Other patients 7 23.28 0.001 74.2 5.31 (2.59–10.87)
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since preventive strategies can be formulated if AKI can be
predicted in advance.
Using sCr level as the ‘‘gold standard’’ of diagnosis of
AKI is another limitation of such studies because sCr is not
an ideal marker of early loss of glomerular filtration or
kidney injury [23]. The best method is to use radio-labeled
tracer clearances to define AKI. However, its use in routine
clinical practice is restrained because it is invasive, time-
consuming and radioactive.
Another limitation lies in IL-18 itself. Cross-sectional
studies indicate that urinary IL-18 levels are markedly
elevated in patients with acute tubular necrosis compared
with healthy controls and a variety of other renal pathol-
ogies, including urinary tract infection, chronic renal
insufficiency, and pre-renal azotemia [24]. Therefore, the
pathophysiology of IL-18 still remains incompletely
understood and the true role of IL-18 may be as a mediator
of specific injury subtypes rather than as a marker of injury.
Though IL-18 can be induced in the proximal tubule after
AKI, and released into urine after cleavage by caspase-1
[25, 26], it can also be derived from lung injury and
myocardial ischemia, etc. Thus, further studies are required
to understand these differences.
Generally speaking, the cost of a single creatinine test
is less than a dollar, while that of IL-18 is five times
higher. In the course of AKI, biochemical indices need to
be monitored and detected many times; given the modest
clinical value of IL-18 and its high cost, serum creatinine
concentration and change might still be a good indicator
rather than IL-18.
Conclusion
In conclusion, this meta-analysis included more than 2,700
patients from 11 studies. The result shows that urine IL-18
level is of diagnostic value for AKI. The diagnostic accu-
racy for AKI tends to be more effective in pediatric patients
and early AKI predictive time. To improve the diagnostic
value of urine IL-18, more appropriately designed inves-
tigations (e.g. with randomized design and eliminating
potential confounders) should be performed.
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